
Quinapril hydrochloride
CAS No. 82586-55-8
Quinapril hydrochloride( CI-906 | PD 109452-2 )
Catalog No. M16066 CAS No. 82586-55-8
Quinapril hydrochloride (Accupril) used in the treatment of hypertension and congestive heart failure.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 34 | In Stock |
![]() ![]() |
100MG | 43 | In Stock |
![]() ![]() |
200MG | 60 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameQuinapril hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionQuinapril hydrochloride (Accupril) used in the treatment of hypertension and congestive heart failure.
-
DescriptionQuinapril hydrochloride (Accupril) used in the treatment of hypertension and congestive heart failure. Quinapril is a prodrug. Quinapril is converted to its active metabolite, quinaprilat, in the liver. Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine and increased concentrations of potassium in the blood.(In Vitro):Quinapril (hydrochloride) (CI-906) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor.
-
In VitroQuinapril (hydrochloride) (CI-906) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor.
-
In Vivo——
-
SynonymsCI-906 | PD 109452-2
-
PathwayEndocrinology/Hormones
-
TargetRAAS
-
RecptorACE
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number82586-55-8
-
Formula Weight474.98
-
Molecular FormulaC25H31CIN2O5
-
Purity>98% (HPLC)
-
SolubilityEthanol: 95 mg/mL (200.0 mM); Water: 95 mg/mL (200.0 mM); DMSO: 18 mg/mL (37.89 mM)
-
SMILESCCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
Nitrosoglutathione
GSNO is an endogenous transnitrosation donor involved in S-nitrosation of a variety of cellular proteins. GSNO, an exogenous NO donor and substrate of rat alcohol dehydrogenase class III isoenzyme, inhibits cerebral angiotensin II-dependent and -independent AT1 receptor responses.
-
Theasinensin C
Theasinensin C is a compound extracted from black tea water with an IC50 value of 40.21 μM for renin activity.
-
N-Acetyl-Ser-Asp-Lys...
Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice.N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a specific substrate for the N-terminal site of ACE and increases 5-fold during ACE inhibitor therapy.??AcSDKP inhibited the proliferation of isolated cardiac fibroblasts (P<0.05) but significantly stimulated the proliferation of vascular smooth muscle cells.?